

Marie Beylot-Barry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/550406/publications.pdf>

Version: 2024-02-01

235
papers

9,983
citations

31976

53
h-index

48315

88
g-index

304
all docs

304
docs citations

304
times ranked

7370
citing authors

#	ARTICLE	IF	CITATIONS
1	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017, 390, 555-566.	13.7	444
2	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. <i>Lancet, The</i> , 2017, 389, 2031-2040.	13.7	438
3	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1192-1204.	10.7	398
4	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S��ary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	1.6	328
5	Blastic NK-Cell Lymphomas (Agranular CD4+CD56+ Hematodermic Neoplasms). <i>American Journal of Clinical Pathology</i> , 2005, 123, 662-675.	0.7	266
6	Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 242-248.	1.2	222
7	Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>Archives of Dermatology</i> , 2007, 143, 1144-50.	1.4	218
8	Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. <i>Blood</i> , 2000, 95, 2212-8.	1.4	215
9	Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 619-626.	1.2	205
10	A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 811-819.	2.5	172
11	Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. <i>Annals of Oncology</i> , 2012, 23, 1074-1080.	1.2	156
12	Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. <i>British Journal of Dermatology</i> , 2013, 169, 579-586.	1.5	141
13	Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. <i>Blood</i> , 2004, 103, 3662-3668.	1.4	139
14	Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?. <i>British Journal of Dermatology</i> , 2010, 162, 74-79.	1.5	136
15	Acute generalized exanthematous pustulosis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 1996, 15, 244-249.	1.6	132
16	The PROCLIFI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357.	1.5	127
17	IRF4 Gene Rearrangements Define a Subgroup of CD30-Positive Cutaneous T-Cell Lymphoma: A Study of 54 Cases. <i>Journal of Investigative Dermatology</i> , 2010, 130, 816-825.	0.7	114
18	High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. <i>JAMA Dermatology</i> , 2014, 150, 1173.	4.1	110

#	ARTICLE	IF	CITATIONS
19	Melanoma and Tumor Thickness. Archives of Dermatology, 1999, 135, 269-74.	1.4	102
20	Statistical Evaluation of Diagnostic and Prognostic Features of CD30+ Cutaneous Lymphoproliferative Disorders. American Journal of Surgical Pathology, 1998, 22, 1192-1202.	3.7	102
21	Genome-Wide Analysis of Cutaneous T-Cell Lymphomas Identifies Three Clinically Relevant Classes. Journal of Investigative Dermatology, 2010, 130, 1707-1718.	0.7	100
22	Clinicopathological Study of 13 Cases of Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa. Dermatology, 2010, 220, 147-153.	2.1	99
23	Specific Skin Lesions in Chronic Myelomonocytic Leukemia. American Journal of Surgical Pathology, 2012, 36, 1302-1316.	3.7	97
24	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. Journal of Investigative Dermatology, 2017, 137, 1984-1994.	0.7	93
25	The Spectrum of Cutaneous Lymphomas in HIV Infection. American Journal of Surgical Pathology, 1999, 23, 1208.	3.7	92
26	Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or SÅ©zary Syndrome. Archives of Dermatology, 2008, 144, 727-33.	1.4	88
27	MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Journal of Investigative Dermatology, 2012, 132, 2118-2120.	0.7	85
28	Histologic and Immunohistologic Characterization of Skin Localization of Myeloid Disorders. American Journal of Clinical Pathology, 2011, 135, 278-290.	0.7	83
29	Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases. British Journal of Dermatology, 2002, 146, 320-324.	1.5	82
30	CDKN2Aâ€“CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Modern Pathology, 2010, 23, 547-558.	5.5	80
31	Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France. JAMA Dermatology, 2014, 150, 535.	4.1	80
32	Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Modern Pathology, 2014, 27, 402-411.	5.5	78
33	Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the SÅ©zary syndrome. The French Study Group on Cutaneous Lymphomas. Blood, 1999, 93, 3637-42.	1.4	77
34	Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood, 2009, 113, 2746-2754.	1.4	76
35	Characterization of t(2;5) Reciprocal Transcripts and Genomic Breakpoints in CD30+ Cutaneous Lymphoproliferations. Blood, 1998, 91, 4668-4676.	1.4	74
36	Evidence that an Identical T Cell Clone in Skin and Peripheral Blood Lymphocytes is an Independent Prognostic Factor in Primary Cutaneous T Cell Lymphomas. Journal of Investigative Dermatology, 2001, 117, 920-926.	0.7	74

#	ARTICLE	IF	CITATIONS
37	Serial chest CT findings in interstitial lung disease associated with polymyositis/dermatomyositis. <i>European Journal of Radiology</i> , 2004, 49, 235-244.	2.6	74
38	Primary Cutaneous Follicular Helper T-cell Lymphoma. <i>Archives of Dermatology</i> , 2012, 148, 832-9.	1.4	74
39	Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. <i>Haematologica</i> , 2014, 99, 527-534.	3.5	73
40	Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 17-26.	2.4	72
41	Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PCLIP). <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 15, 1555-1562.	1.0	70
42	Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing*. <i>British Journal of Dermatology</i> , 2020, 183, 866-874.	1.5	65
43	Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. <i>British Journal of Dermatology</i> , 2011, 165, 985-989.	1.5	63
44	Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e686-e689.	2.4	61
45	Cutaneous Sarcoidosis Successfully Treated With Low Doses of Thalidomide. <i>Archives of Dermatology</i> , 1998, 134, 1045-1046.	1.4	61
46	The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: A prospective study. <i>International Journal of Cancer</i> , 2002, 102, 34-38.	5.1	60
47	Successful Treatment of Subcorneal Pustular Dermatitis (Sneddon-Wilkinson Disease) by Acitretin: Report of a Case. <i>Dermatology</i> , 1999, 199, 153-155.	2.1	59
48	Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. <i>British Journal of Dermatology</i> , 2015, 172, 1547-1554.	1.5	58
49	Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 13-16.	2.4	57
50	Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy. <i>Acta Dermato-Venereologica</i> , 2017, 97, 358-364.	1.3	57
51	Human Immunodeficiency Virus Type 1 Replication Within Cystic Lymphoepithelial Lesion of the Salivary Gland. <i>American Journal of Clinical Pathology</i> , 1993, 100, 41-46.	0.7	56
52	Pseudoepitheliomatous hyperplasia in cutaneous T-cell lymphoma. A clinical, histopathological and immunohistochemical study with particular interest in epithelial growth factor expression. <i>British Journal of Dermatology</i> , 1999, 140, 421-426.	1.5	56
53	Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease. <i>British Journal of Dermatology</i> , 2003, 149, 181-184.	1.5	56
54	Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. <i>British Journal of Dermatology</i> , 2009, 161, 660-663.	1.5	56

#	ARTICLE	IF	CITATIONS
55	Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage I-IVa mycosis fungoides/Sézary syndrome. <i>British Journal of Dermatology</i> , 2016, 175, 80-88.	1.5	56
56	Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. <i>British Journal of Dermatology</i> , 2020, 182, 1111-1119.	1.5	55
57	Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2003, 119, 414-423.	0.7	51
58	Neoplastic Cells Do Not Carry bcl2-JH Rearrangements Detected in a Subset of Primary Cutaneous Follicle Center B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2004, 28, 748-755.	3.7	51
59	Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids. <i>Archives of Dermatology</i> , 2005, 141, 1117.	1.4	51
60	GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 647-656.	1.5	51
61	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752.	3.5	50
62	CD30-Positive Cutaneous Large Cell Lymphomas: A Comparative Study of Clinicopathologic and Molecular Features of 16 Cases. <i>American Journal of Clinical Pathology</i> , 1996, 105, 440-450.	0.7	47
63	Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2085-2088.e14.	0.7	47
64	MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1741-1744.	0.7	46
65	Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. <i>American Journal of Pathology</i> , 1996, 149, 483-92.	3.8	46
66	A Prospective Study of Cutaneous Intolerance to Topical Mechlorethamine Therapy in Patients With Cutaneous T-Cell Lymphomas. <i>Archives of Dermatology</i> , 1999, 135, 1349-53.	1.4	45
67	Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. <i>European Journal of Cancer</i> , 2021, 157, 474-484.	2.8	45
68	Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. <i>British Journal of Dermatology</i> , 2001, 144, 1235-1238.	1.5	44
69	Common chromosomal abnormalities in mycosis fungoides transformation. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 828-838.	2.8	44
70	Relevance of Vertical Growth Pattern in Thin Level II Cutaneous Superficial Spreading Melanomas. <i>American Journal of Surgical Pathology</i> , 2003, 27, 717-724.	3.7	42
71	Efficacy and Safety of Tumor Necrosis Factor Inhibitors in Acute Generalized Pustular Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 1423.	1.4	42
72	Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. <i>British Journal of Dermatology</i> , 2012, 167, 417-423.	1.5	42

#	ARTICLE	IF	CITATIONS
73	Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. <i>Oncologist</i> , 2016, 21, 76-83.	3.7	42
74	Molecular alterations and tumor suppressive function of the <i>DUSP22</i> (Dual Specificity) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 Td	1.8	41
75	Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy. <i>JAMA Dermatology</i> , 2020, 156, 545.	4.1	40
76	Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*. <i>British Journal of Dermatology</i> , 2021, 184, 1059-1067.	1.5	39
77	Value of Interphase FISH for the Diagnosis of t(11;14)(q13;q32) on Skin Lesions of Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2002, 118, 832-841.	0.7	38
78	Inactivation of p16 INK4a /CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 607-620.	2.8	38
79	Diagnostic and Prognostic Value of <i>BCL2</i> Rearrangement in 53 Patients With Follicular Lymphoma Presenting as Primary Skin Lesions. <i>American Journal of Clinical Pathology</i> , 2015, 143, 362-373.	0.7	38
80	PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>American Journal of Surgical Pathology</i> , 2018, 42, 326-334.	3.7	38
81	Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab. <i>Archives of Dermatology</i> , 2009, 145, 329-30.	1.4	37
82	CD20 Antigen May Be Expressed by Reactive or Lymphomatous Cells of Transformed Mycosis Fungoides. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1845-1854.	3.7	37
83	Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 293-300.	2.4	36
84	Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 2020, 44, 862-872.	3.7	36
85	Primary Cutaneous <i>Nocardia asteroides</i> Infection after Heart Transplantation. <i>Dermatology</i> , 1998, 196, 246-247.	2.1	35
86	Herpes simplex virus type 2 ascending myeloradiculitis: MRI findings and rapid diagnosis by the polymerase chain method.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 869-870.	1.9	34
87	Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1796-1802.	6.7	33
88	Drug-induced linear IgA bullous dermatosis. <i>Journal of the American Academy of Dermatology</i> , 1995, 32, 296.	1.2	32
89	Oral Contraceptives and Cyproterone Acetate in Female Acne Treatment. <i>Dermatology</i> , 1998, 196, 148-152.	2.1	31
90	Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. <i>British Journal of Dermatology</i> , 2012, 167, 643-648.	1.5	31

#	ARTICLE	IF	CITATIONS
91	Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. <i>Modern Pathology</i> , 2018, 31, 1332-1342.	5.5	31
92	Infectious events and associated risk factors in mycosis fungoides/S�azary syndrome: a retrospective cohort study. <i>British Journal of Dermatology</i> , 2018, 179, 1322-1328.	1.5	31
93	Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2046-2054.	2.4	30
94	Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 437-440.	2.4	30
95	Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm. <i>Supportive Care in Cancer</i> , 2012, 20, 1395-1404.	2.2	29
96	Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1984-1992.	2.4	29
97	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. <i>Blood</i> , 2020, 135, 1058-1061.	1.4	29
98	Lymphomatoid contact dermatitis caused by isopropyl-diphenylenediamine: Two cases. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 152-153.	2.9	28
99	Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2334-2342.e8.	0.7	28
100	Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases. <i>Histopathology</i> , 2019, 74, 1067-1080.	2.9	28
101	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1982-1989.	0.7	27
102	Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development. <i>British Journal of Dermatology</i> , 2016, 175, 636-638.	1.5	26
103	Lichen planus following hepatitis B vaccination. <i>British Journal of Dermatology</i> , 1998, 139, 350-350.	1.5	25
104	Dermatophytic Granuloma Caused by <i>Microsporum canis</i> in a Heart-Lung Recipient. <i>Dermatology</i> , 1999, 198, 317-319.	2.1	25
105	Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 3-12.	2.4	25
106	Risk factors, clinical variants and therapeutic outcome of retronychia: a retrospective study of 18 patients. <i>European Journal of Dermatology</i> , 2016, 26, 377-381.	0.6	25
107	Mycosis fungoides mimicking granuloma annulare. <i>British Journal of Dermatology</i> , 2002, 146, 1102-1103.	1.5	24
108	Primary Cutaneous T-Cell Lymphomas Do not Show Specific NAV3 Gene Deletion or Translocation. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2458-2466.	0.7	24

#	ARTICLE	IF	CITATIONS
109	Symptoms dermatologists should look for in daily practice to improve detection of psoriatic arthritis in psoriasis patients: an expert group consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 27-32.	2.4	24
110	Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma. <i>Blood</i> , 2014, 123, 1850-1859.	1.4	24
111	Defining and recognising locally advanced basal cell carcinoma. <i>European Journal of Dermatology</i> , 2015, 25, 586-594.	0.6	24
112	Chromosomal imbalances: a hallmark of tumour relapse in primary cutaneous CD30+ T-cell lymphoma. <i>Journal of Pathology</i> , 2003, 201, 421-429.	4.5	22
113	Large cell transformation of mycosis fungoides: tetraploidization within skin tumor large cells. <i>Cancer Genetics and Cytogenetics</i> , 2005, 163, 1-6.	1.0	21
114	Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1581-1592.	3.7	21
115	Cutaneous localization of chronic lymphocytic leukemia at the site of chickenpox. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 98-99.	1.2	20
116	Disseminated Cutaneous Lymphoid Hyperplasia of 12 Years' Duration Triggered by Vaccination. <i>Dermatology</i> , 2010, 220, 176-179.	2.1	20
117	Lymphomatoid papulosis type D: an aggressive histology for an indolent disease. <i>British Journal of Dermatology</i> , 2013, 169, 1157-1159.	1.5	20
118	Sézary syndrome without erythroderma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1003-1009.e1.	1.2	19
119	T-cell papulosis associated with B-cell malignancy: a distinctive clinicopathologic entity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1469-1475.	2.4	19
120	Pityriasis rubra pilaris and hypothyroidism. Efficacy of thyroid hormone replacement therapy in skin recovery. <i>British Journal of Dermatology</i> , 2007, 156, 606-607.	1.5	18
121	Primary cutaneous follicle center lymphoma with Hodgkin and Reed-Sternberg-like cells: a new histopathologic variant. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 797-801.	1.3	18
122	Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*. <i>British Journal of Dermatology</i> , 2021, 184, 524-531.	1.5	18
123	Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 97-105.	0.4	18
124	p53 oncoprotein expression in cutaneous lymphoproliferations. <i>Archives of Dermatology</i> , 1995, 131, 1019-1024.	1.4	18
125	Contribution of histopathologic and molecular analyses to the diagnosis of cutaneous B-cell infiltrates. <i>Modern Pathology</i> , 1996, 9, 1147-55.	5.5	18
126	Management of granulomatous foreign body reaction to fillers with methotrexate. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 817-820.	2.4	17

#	ARTICLE	IF	CITATIONS
127	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-“PD-1 Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1821-1829.	3.0	17
128	Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/S“zary syndrome cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 404-410.	1.2	16
129	PLCG1 Gene Mutations Are Uncommon in Cutaneous T-Cell Lymphomas. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2334-2337.	0.7	16
130	Expression of S“zary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides. <i>Journal of Investigative Dermatology</i> , 2016, 136, 317-320.	0.7	16
131	A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. <i>European Journal of Dermatology</i> , 2017, 27, 286-294.	0.6	16
132	Xenograft and cell culture models of S“zary syndrome reveal cell of origin diversity and subclonal heterogeneity. <i>Leukemia</i> , 2021, 35, 1696-1709.	7.2	16
133	Clinical factors predictive for histological aggressiveness of basal cell carcinoma: A prospective study of 2274 cases. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 23-27.	1.0	16
134	Erythema annulare centrifugum revealing chronic lymphocytic leukaemia. <i>British Journal of Dermatology</i> , 2007, 157, 1045-1047.	1.5	15
135	Predictors of long-term drug survival for infliximab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 96-101.	2.4	15
136	Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database. <i>British Journal of Dermatology</i> , 2019, 181, 616-618.	1.5	15
137	Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. <i>Blood</i> , 2020, 135, 1101-1110.	1.4	15
138	Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology. <i>British Journal of Dermatology</i> , 2021, 184, 963-965.	1.5	15
139	Pilotropic mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 501.	1.2	14
140	Ki-1-Positive Large-Cell Cutaneous Lymphoma Mimicking a Stewart-Treves Angiosarcoma. <i>Dermatology</i> , 1995, 190, 77-82.	2.1	13
141	p53 Oncoprotein Expression in Cutaneous Lymphoproliferations. <i>Archives of Dermatology</i> , 1995, 131, 1019.	1.4	13
142	Treatment of pityriasis rubra pilaris: a retrospective study of 14 patients. <i>Journal of Dermatological Treatment</i> , 1999, 10, 113-117.	2.2	13
143	Oral erosive lichen planus and Good's syndrome: just a coincidence or a direct link between the two diseases?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 506-507.	2.4	13
144	Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors. <i>Acta Dermato-Venereologica</i> , 2017, 97, 731-734.	1.3	13

#	ARTICLE	IF	CITATIONS
145	Paradoxical psoriasiform reactions to antitumour necrosis factor- α drugs in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2018, 178, 281-283.	1.5	13
146	TP53 alterations in primary and secondary Sezary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma. <i>PLoS ONE</i> , 2017, 12, e0173171.	2.5	13
147	<sc>BRAF</sc> inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 392-393.	2.4	12
148	Exploring <i>hTERT</i> promoter methylation in cutaneous T-cell lymphomas. <i>Molecular Oncology</i> , 2022, 16, 1931-1946.	4.6	12
149	Folliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or <sc>MALT</sc> lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 77-85.	2.4	11
150	Intrahepatic Xenograft of Cutaneous T-Cell Lymphoma Cell Lines. <i>American Journal of Pathology</i> , 2016, 186, 1775-1785.	3.8	11
151	Complete Remission of Squamous Cell Carcinoma After Treatment With Panitumumab in a Patient With Cetuximab-Induced Anaphylaxis. <i>JAMA Dermatology</i> , 2016, 152, 343.	4.1	11
152	Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e498-e501.	2.4	11
153	Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type. <i>Journal of Dermatological Science</i> , 2017, 88, 238-246.	1.9	11
154	Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients. <i>European Journal of Dermatology</i> , 2017, 27, 271-274.	0.6	11
155	Urticaria and hepatitis C infection. <i>British Journal of Dermatology</i> , 1998, 138, 194-195.	1.5	11
156	Meningeal involvement by a transformed mycosis fungoides following Hodgkin's disease. <i>British Journal of Dermatology</i> , 1999, 141, 909-913.	1.5	10
157	Is bone marrow biopsy necessary in patients with mycosis fungoides and Sezary syndrome? A histological and molecular study at diagnosis and during follow-up. <i>British Journal of Dermatology</i> , 2005, 152, 1378-1379.	1.5	10
158	IRF4 Expression without IRF4 Rearrangement Is a General Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1470-1472.	0.7	10
159	Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1920-1929.	2.4	10
160	Histiocytic sarcoma that mimicks benign histiocytosis. <i>Journal of Cutaneous Pathology</i> , 1996, 23, 275-283.	1.3	9
161	A suggested protocol for obtaining high-quality skin metaphases from primary cutaneous T-cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2006, 167, 89-91.	1.0	9
162	Acquired Dermal Melanocytosis of the Back in a Caucasian Woman. <i>American Journal of Dermatopathology</i> , 2012, 34, 562-563.	0.6	9

#	ARTICLE	IF	CITATIONS
163	Red fingers syndrome: acrosyndrome related to vascular growth endothelial factor?. Clinical and Experimental Dermatology, 2001, 26, 219-220.	1.3	8
164	Necrotic livedo after vertebroplasty. British Journal of Dermatology, 2007, 156, 382-383.	1.5	8
165	Acral Acquired Cutis Laxa Associated with IgA Multiple Myeloma, Joint Hyperlaxity and Urticarial Neutrophilic Dermatitis. Acta Dermato-Venereologica, 2014, 94, 743-744.	1.3	8
166	Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers. Journal of Dermatological Treatment, 2014, 25, 75-77.	2.2	8
167	Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma. JAMA Dermatology, 2015, 151, 1030.	4.1	8
168	Pyoderma gangrenosum with extensive pulmonary involvement. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e214-e216.	2.4	8
169	Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology. British Journal of Dermatology, 2021, 185, 658-660.	1.5	8
170	Clinical presentation, therapeutic approach and outcome of primary cutaneous marginal zone Bâ€cell lymphoma presenting as AL amyloidoma of the skin. British Journal of Dermatology, 2019, 181, 607-609.	1.5	7
171	Diagnosis and treatment of lymphomas in the era of epigenetics. Blood Reviews, 2021, 48, 100782.	5.7	7
172	Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database. ESMO Open, 2021, 6, 100284.	4.5	7
173	Gluteal Pigmentation after Intramuscular Iron Injections. Dermatology, 1996, 192, 187-188.	2.1	6
174	Treatment (biotherapy excluded) of psoriatic arthritis: an appraisal of methodological quality of international guidelines. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 33-39.	2.4	6
175	Pyoderma gangrenosum misdiagnosed as necrotising fasciitis or a real association between the two?. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e305-e306.	2.4	6
176	Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. Clinical and Experimental Dermatology, 2021, 46, 1441-1451.	1.3	6
177	Telomeric Repeat-Containing RNA (TERRA): A Review of the Literature and First Assessment in Cutaneous T-Cell Lymphomas. Genes, 2022, 13, 539.	2.4	6
178	Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines: â€specificâ€™ patterns in a series of 192 patients. British Journal of Dermatology, 2022, 187, 615-617.	1.5	6
179	Cutaneous Lymphocyte Antigen Is a PotentialâTherapeutic Target in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2022, 142, 3243-3252.e10.	0.7	6
180	Systemic sarcoidosis revealed by sarcoidal granulomas on tattoo. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1045-1046.	2.4	5

#	ARTICLE	IF	CITATIONS
181	Treatment of mycosis fungoides and SÅ©zary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma. <i>British Journal of Dermatology</i> , 2019, 180, 423-424.	1.5	5
182	Mogamulizumabâ€induced granulomatous dermatitis of the scalp: a distinct entity associated with clinical response. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	5
183	Three cases of bacterial osteomyelitis associated with hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2019, 180, 1537-1538.	1.5	4
184	Impact of the French guidelines on the prescribing habits of systemic treatments for moderateâ€toâ€severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e747-e748.	2.4	4
185	Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts. <i>Dermatology</i> , 2021, 237, 748-758.	2.1	4
186	Clinicopathologic analysis of trichoblastoma and comparison with nodular basal cell carcinoma. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 177-182.	1.0	4
187	Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Psoriasis Patients from the PsoBioTeq Cohort. <i>Acta Dermato-Venereologica</i> , 2021, , .	1.3	4
188	Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling. <i>PLoS ONE</i> , 2022, 17, e0266978.	2.5	4
189	The hand of the wine grower: hypothenar hammer syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 22, 070612045632002-???	2.4	3
190	Aggressive intermediate cell histiocytosis successfully treated by 2â€chlorodeoxyadenosine. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1153-1156.	2.4	3
191	Intravenous cidofovir for diffuse genital warts in the setting of multifactorial immunosuppression. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e162-e163.	2.4	3
192	Severe hypercalcemia complicating granulomatous slack skin disease: an exceptional case. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e354-e356.	2.4	3
193	Challenges in Assessing MYC Rearrangement in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. <i>American Journal of Surgical Pathology</i> , 2020, 44, 424-427.	3.7	3
194	Acquired cutis laxa associated with neutrophilic urticarial dermatosis. <i>International Journal of Dermatology</i> , 2021, 60, 771-772.	1.0	3
195	Lack of clinical relevance of blood clonality in primary cutaneous marginal zone B-cell lymphoma. <i>European Journal of Dermatology</i> , 2021, 31, 94-96.	0.6	3
196	Nonâ€acral skin manifestations during the COVIDâ€19 epidemic: COVIDSKIN study by the French Society of Dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e539-e541.	2.4	3
197	Vismodegib efficacy in unresectable trichoblastic carcinoma: A multicenter study of 16 cases. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1365-1366.	1.2	3
198	Bone involvement in two cases of thoracic primary cutaneous diffuse large B-cell lymphoma, leg type. <i>European Journal of Dermatology</i> , 2011, 21, 744-749.	0.6	3

#	ARTICLE	IF	CITATIONS
199	Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of SÃ©zary Cells. <i>Frontiers in Oncology</i> , 2021, 11, 775253.	2.8	3
200	A Multicentre Randomised Controlled Study Evaluating the Effect of a Standardised Education Programme on Quality of Life, Disease Severity, and Disease Knowledge in Patients with Moderate-To-Severe Psoriasis: The EDUPSO Study. <i>Dermatology</i> , 2021, , 1-10.	2.1	3
201	Attitudes, Barriers, Motivations to Sun Protection in Reunion Islandâ€™s Schools: Qualitative Study. <i>Risk Management and Healthcare Policy</i> , 2022, Volume 15, 895-900.	2.5	3
202	About some red faces. <i>Annales De Dermatologie Et De Venereologie</i> , 2011, 138, S201-S206.	1.0	2
203	Sirolimus-related anal ulceration in a female patient after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 132-133.	2.4	2
204	Facilitators of and obstacles to consultation in patients with advanced basal cell carcinoma: a French pilot study. <i>Archives of Dermatological Research</i> , 2021, 313, 829-835.	1.9	2
205	Vindesine dexamethasone as a therapeutic option in elderly blastic plasmacytoid dendritic cell neoplasms: a monocentric experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-3.	1.3	2
206	From neglect to earlier diagnosis: a qualitative meta-synthesis of psycho-social factors associated with consultation delay in advanced basal cell carcinoma. <i>Psychology, Health and Medicine</i> , 2022, 27, 1793-1804.	2.4	2
207	Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous Tâ€¢cell lymphoma: nine cases. <i>British Journal of Dermatology</i> , 2021, 185, 1061-1063.	1.5	2
208	Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort. <i>British Journal of Dermatology</i> , 2021, 185, 1052-1054.	1.5	2
209	Surgical treatment of rhinophyma: Retrospective monocentric study and literature review. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 172-176.	1.0	2
210	Impact of Childhood Onset Psoriasis on Addictive Behaviours, Socioeconomic and Educational Data in Adulthood. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00733.	1.3	2
211	DÃ©finition, classification, diagnostic clinique et histologique des lymphomes T cutanÃ©s. <i>Annales De Dermatologie Et De Venereologie</i> , 2005, 132, 5-10.	1.0	1
212	Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. <i>British Journal of Dermatology</i> , 2021, 184, 356-358.	1.5	1
213	Mycosis fongoÃ«de et lymphomes T Ã©rythrodermiques. <i>Annales De Dermatologie Et De VÃ©nÃ©rologie, FMC</i> , 2021, 1, 40-47.	0.0	1
214	Characterization of t(2;5) Reciprocal Transcripts and Genomic Breakpoints in CD30+ Cutaneous Lymphoproliferations. <i>Blood</i> , 1998, 91, 4668-4676.	1.4	1
215	Lymphomes cutanÃ©s secondaires. , 2013, , 205-223.		1
216	How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1202-1210.	1.3	1

#	ARTICLE	IF	CITATIONS
217	Histiocitosis de células de Langerhans y sin células de Langerhans. EMC - Dermatología, 2003, 37, 1-11.	0.1	0
218	Cas n° 4. Annales De Pathologie, 2007, 27, 295-297.	0.1	0
219	Cas n° 2. Annales De Pathologie, 2007, 27, 290-292.	0.1	0
220	Márgenes de resección oncológica en cirugía dermatológica. EMC - Dermatología, 2013, 47, 1-9.	0.1	0
221	Recommandations pour le traitement des lymphomes T cutanés. , 2013, , 259-268.		0
222	Amélioration durable des manifestations cutanées et de la fonction physique avec le secukinumab versus l'ustakinumab chez les patients atteints de psoriasis modéré à sévère et de rhumatisme psoriasique concomitant: résultats de l'étude CLEAR à 1 an. Revue Du Rhumatisme (Edition Française), 2016, 83, A174.	0.0	0
223	« Malignant » Rosacea as a sign of systemic marginal zone lymphoma. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e71-e72.	2.4	0
224	Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains: reply from the authors. British Journal of Dermatology, 2020, 183, 1151-1152.	1.5	0
225	Disseminated cutaneous granulomatosis as a manifestation of myelodysplastic syndrome. International Journal of Dermatology, 2021, 60, 628-630.	1.0	0
226	Characterization of advanced basal cell carcinoma patients progressing while receiving Hedgehog pathway inhibitors. British Journal of Dermatology, 2021, , .	1.5	0
227	Mogalizumab-induced granulomatous eruption of the scalp: a distinct entity associated with clinical response?. European Journal of Cancer, 2021, 156, S49-S50.	2.8	0
228	Lymphomes T cutanés (hors mycosis fonguïde et syndrome de Sézary). , 2009, , 25-35.		0
229	Lymphoproliférations cutanées CD30+: lymphome cutané primitif à grandes cellules T CD30+ et papulose lymphomatoïde. , 2013, , 95-110.		0
230	Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell Lymphomas. American Journal of Clinical Pathology, 2003, 119, 0-0.	0.7	0
231	Place de la radiothérapie dans le traitement des lymphomes cutanés. Annales De Dermatologie Et De Vénéréologie, FMC, 2022, , .	0.0	0
232	Accuracy of Store-and-Forward Tele dermatology for the Diagnosis of Skin Cancer: The Nouvelle-Aquitaine Experience. Iproceedings, 2021, 6, e35404.	0.1	0
233	CITY-PSO: Prescribing behaviour of French private-practice dermatologists in psoriasis management: An observational, multicentre, cross-sectional study. Annales De Dermatologie Et De Venereologie, 2022, , .	1.0	0
234	The harmful effects of aesthetic care: Dealing with new kinds of exogenous acne. Annales De Dermatologie Et De Venereologie, 2022, , .	1.0	0

#	ARTICLE	IF	CITATIONS
235	Primary intralymphatic histiocytosis: Case report and literature review. Annales De Dermatologie Et De Venereologie, 2022, , .	1.0	0